Valeant Pharmaceuticals International (now Bausch Health)

Between 2002 and 2007, Valeant Pharmaceuticals was an unremarkable mid-size specialty pharma company generating roughly $700M–$900M in annual revenue with conventional R&D-driven drug development. In 2008, activist investor ValueAct Capital backed the appointment of McKinsey consultant J. Michael Pearson as CEO. Pearson arrived with a blunt thesis: pharmaceutical R&D was a poor return on capital. Most drug candidates failed; the few that succeeded were routinely out-competed or genericized. His alternative: acquire drugs that already worked, slash every cost not directly tied to sales, raise prices aggressively on acquired products, and fund the entire cycle with cheap debt. The model superficially resembled what Constellation Software, Halma, and the Nordic acquirers were doing — high acquisition volume, disciplined cost control, rapid EPS growth. But the underlying logic was inverted. Where healthy serial acquirers create operating leverage by improving what they buy, Valeant’s model extracted value by repricing it and deferring its decay. By 2013, Wall Street had anointed Valeant the future of pharmaceuticals. Analysts pointed to the same metrics that define compounders: revenue growing at 30–40% annually, acquisition multiples below peers, adjusted EPS up over 10x in five years. The structural difference — that Valeant’s cash flows depended on continuously raising prices on drugs with no competitive alternatives and continuously acquiring the next batch before the last one genericized — was not yet visible in the numbers.

Pearson executed over 100 acquisitions between 2008 and 2015. The playbook was mechanically consistent: identify an asset with durable pricing power (often a branded drug with no generic equivalent and an inelastic patient base), acquire it at a competitive price, immediately cut R&D to near-zero (Valeant spent roughly 3% of revenue on R&D versus the pharmaceutical industry average of 15–20%), replace the prior management, and raise the acquired drug’s price — sometimes immediately and dramatically. Notable price increases post-acquisition became a pattern: Valeant raised prices on dozens of drugs by 200–800% within months of acquisition. Key acquisitions included Medicis Pharmaceutical (2012, $2.6B, dermatology), Bausch & Lomb (2013, $8.7B, eye care), and Salix Pharmaceuticals (2015, $15.8B, gastrointestinal), the last of which pushed net debt above $30B. Valeant also built an unusual channel strategy through specialty pharmacy Philidor Rx Services, a captive distribution network designed to maximize reimbursements and reduce generic substitution — an arrangement that was undisclosed to investors. The company reported financial results using adjusted cash EPS, a metric that excluded acquisition-related amortization and restructuring charges. This measure showed strong consistent growth; GAAP net income was persistently negative due to goodwill amortization from the acquisition chain. The stock peaked at approximately $263 per share in August 2015, giving Valeant a market capitalization above $90B and making it briefly the most valuable company in Canada.